<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522158</url>
  </required_header>
  <id_info>
    <org_study_id>KA 05/75</org_study_id>
    <nct_id>NCT00522158</nct_id>
  </id_info>
  <brief_title>Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to compare the effect of achieving an LDL-cholesterol &lt;70 vs an LDL-cholesterol &lt;100&#xD;
      mg/dL with simvastatin or atorvastatin on adrenal and testicular steroidogenesis, and&#xD;
      cognition in diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>LDL Cholesterol</condition>
  <condition>Cognition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with controlled type 2 diabetes mellitus with overt CVD&#xD;
&#xD;
          -  patients with controlled type 2 diabetes mellitus over the age of 40 years without&#xD;
             overt CVD,but with one or more major cardiovascular risk factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled hypertension (systolic blood pressure &gt;180 mm Hg or diastolic blood&#xD;
             pressure &gt;95 mm Hg); evidence of active active liver disease or hepatic dysfunction&#xD;
             defined as a level of liver transaminases &gt;2 times the upper limit of normal;&#xD;
             uncontrolled myocardial ischaemia; congestive heart failure (New York Heart&#xD;
             Association classification IIIb or IV); hemodynamically important valvular disease;&#xD;
             secondary hypercholesterolemia; gastrointestinal disease that might limit drug&#xD;
             absorption or partial ileal bypass; myopathy, or rhabdomyolysis; a known&#xD;
             hypersensitivity to statins; using any androgenic, estrogenic, progestogenic,&#xD;
             antiandrogenic, or antiestrogenic agents or medications that can alter the gonadal&#xD;
             steroid milieu; using systemic immunosuppressants or anticoagulants; plasma creatine&#xD;
             kinase levels &gt;50% above the upper limit of normal,transient ischaemic attack or&#xD;
             stroke in past,severe hypertriglyceridaemia (fasting triglyceride level ≥350&#xD;
             mg/dl,Currently on psychotropic medications, steroids, opiate analgesics, Known case&#xD;
             of major neuropsychiatric illness,Poor cognition at baseline [Mini-Mental State&#xD;
             Examination(MMSE) score ≤24],Physically or mentally unable to complete tests, history&#xD;
             of other risk factors for hearing loss and/or conventional assessment that presented&#xD;
             conductive hearing loss, confirmed by acoustic immittance measurement;presence of&#xD;
             non-auditory associated disorders that could lead to long-latency potentials, such as&#xD;
             neurological diseases or syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zehra Berberoglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University Faculty of Medicine</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2007</study_first_posted>
  <last_update_submitted>August 28, 2007</last_update_submitted>
  <last_update_submitted_qc>August 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

